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Gp160-directed antibody-mediated neutralization is thought to function by at least two different mechanisms that impair
virus entry into the host cell: inhibition of virus attachment and inhibition of virus–cell membrane fusion. Previously, the
neutralization spectra of sera derived from human immunodeficiency virus type 1 (HIV-1) infected patients were determined
using 17 primary isolates belonging to HIV-1 group M (env clades A–H) and group O. The sera could be categorized as potent
broad cross-neutralizing, limited cross-neutralizing, and nonneutralizing sera. The aim of this study was to examine whether
the neutralizing capacity of polyclonal human sera correlates with their capacity to inhibit the attachment of infectious virions
to the surface of peripheral blood mononuclear cells. A 100% correlation was found between the broad cross-neutralizing
capacity and the ability to inhibit binding of primary isolates belonging to different genetic clades and groups to peripheral
blood mononuclear cells. These results may indicate that broad cross-neutralizing antibodies are directed against those
conserved regions on gp120 that interact with the cell receptor(s) and that those antibodies can therefore interfere with the
binding of virus to the host cell. © 2001 Academic PressINTRODUCTION
During the course of a human immunodeficiency virus
(HIV) infection, patients develop an antibody response
directed against viral antigens. The neutralizing antibody
activity is directed primarily against the surface envelope
glycoprotein, gp120 (Burton and Montefiori, 1997; Poig-
nard et al., 1996). Comparison of the gp120 amino acid
sequences has found similarities among different HIV-1
isolates and allows division of gp120 into distinct vari-
able (V1–V5) and constant regions (Starcich et al., 1986).
Variable regions (V1–V4) form surface-exposed loops,
probably flexible structures, and are highly hydrophilic.
Constant regions are sequestered predominantly within
the conformational rigid core of gp120 and form discon-
tinuous structures (Moore et al., 1994). Neutralizing an-
tibodies are elicited both to the variable and to the
conserved regions. The antibody response that appears
early after infection is directed at epitopes in the variable
regions and lacks broad cross-neutralizing activity when
tested against multiple isolates. Antibodies with broad
cross-neutralizing activity are directed against more con-
served discontinuous regions and develop later in the
progression of the disease (Moog et al., 1997).
1 To whom reprint requests should be addressed at Institute of
ropical Medicine-Department of Microbiology, Nationalestraat 155,
000 Antwerpen, Belgium. Fax: 1132 3 247 63 33. E-mail:
vdgroen@itg.be.
305HIV-1 infection of host cells is a multistep sequential
process. The first high-affinity interaction between virion
and the host cell involves the attachment of the viral
glycoprotein gp120 to the CD4 receptor, which results in
a CD4-binding-induced conformational change in gp120.
This change is required for the subsequent interaction
between gp120 and an appropriate coreceptor, one of
several members of the chemokine receptor family. A
second conformational change is thought to expose the
transmembrane gp41 protein of the virion to initiate the
last step of infection, i.e., the membrane fusion between
the viral and the cellular membranes. Recently, the three-
dimensional structure of recombinant gp120, complexed
with CD4 and an antibody directed against the region
that interacts with the coreceptor, was elucidated
(Kwong et al., 1998). The resolution of the gp120 core
structure has demonstrated the presence of highly con-
served residues in the CD4-binding region as well as in
the chemokine-receptor-binding region of gp120. Based
on these new findings, two major mechanisms for broad
cross-neutralizing antibodies against gp120 are pro-
posed: inhibition of attachment of gp120 to the CD4
receptor and inhibition of binding to the appropriate
coreceptor (Wyatt et al., 1998).
A previous study determined the neutralization spectra
of sera derived from HIV-1-infected patients against 17
primary isolates belonging to HIV-1 group M (n 5 14;
env clades A–H) and group O (n 5 3) (Beirnaert et al.,
2000). The sera could be grouped into three categories.
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306 BEIRNAERT ET AL.Potent broad cross-neutralizing sera were able to neu-
tralize all 17 primary isolates, limited cross-neutralizing
sera were able to neutralize some but not all 17 primary
isolates, and nonneutralizing sera were not able to neu-
tralize any of the primary isolates. The present study was
designed to examine the impact of polyclonal human
HIV-1 sera on the attachment of infectious primary HIV-1
isolates to the surface of peripheral blood mononuclear
cells (PBMCs) and to investigate whether there is a
correlation between neutralizing capacity and inhibition
of binding. This study is innovative in the following as-
pects. Human sera from naturally HIV-1-infected individ-
uals, which showed different neutralizing activity profiles
going from broad cross-neutralizing to nonneutralizing,
were examined. Nine different primary isolates, belong-
ing to different subtypes in groups M (n 5 8) and O (n 5
1), were analyzed. A novel, 1-day virus-binding assay
was developed, which measures virions directly on
PBMCs as host cells and uses similar assay conditions
as in the classical neutralization assay (Beirnaert et al.,
2000).
RESULTS
Detection of viral attachment to PBMCs
In order to monitor whether polyclonal sera are able to
inhibit attachment of infectious virions to the surface of
PBMCs, it was necessary to develop an assay that can
FIG. 1. Virus was incubated with PHA-stimulated PBMCs under differ
using the Vironostika HIV-1 Antigen Microelisa system (Organon Teknmeasure bound virions. Culture supernatant of virus iso-
late VI525 at a concentration of 5 ng p24/ml was incu-
9
ibated with PBMCs under varying incubation conditions
regarding temperature (4°C/20°C/37°C) and time (1 h/2
h). Next, cells were washed and lysed and the p24
antigen concentration was determined. After five wash-
ings no residual input p24 antigen could be measured in
the wash supernatants. Under all conditions, similar p24
concentrations were measured (120–145 pg p24/ml) (Fig.
1). Further experiments were carried out at 37°C, to
resemble the natural physiological conditions in the in
vivo situation and during 2 h. These conditions are also
used in the classical neutralization assay (Beirnaert et
al., 2000).
The use of detergent to lyse the virions to quantify the
presence of viral antigen implicates that, in addition to
attached extracellular virus, intracellular virus also can
be measured. To determine whether fusion and/or endo-
cytosis occurs under the incubation conditions used, a
trypsin treatment of cells was carried out as described
under Materials and Methods. The p24 concentration in
the supernatant represents the attached extracellular
virus, while the p24 concentration in the lysed cells
represents the amount of intracellular virus. The experi-
ments were performed using primary virus isolate VI525,
which is a mixture of two virus isolates belonging to
different subtypes (env A and env G) and different phe-
otypes (CCR5 coreceptor-using and CXCR4 coreceptor-
sing) (Beirnaert et al., 2000). The results presented in
ig. 2 show that on average 89.3% (ranging from 84 to
ditions. Cells were washed and lysed and viral antigen was measured
e results are the mean of quadruplicate experiments.5%) of the p24 antigen was found in the trypsin-contain-
ng supernatant, correlating with extracellular virus, and
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lysed cells, correlating with intracellular virus. These
results show that, under the assay conditions used, the
virions have attached to the cell and only a minority of
the virus particles has fused or been endocytosed by the
cells.
A serial dilution of virus supernatant for each of the
nine virus isolates was examined for its efficiency to bind
to the surface of PBMCs. For all viruses a dose-depen-
dent correlation was obtained between the amount of
input virus and the amount of virus bound to the host
cells. The best linear correlation was found for an input
virus concentration in the range of 3–12 ng p24/ml, which
resulted in 101–204 pg p24/ml bound to the surface. The
use of a higher concentration of input virus (.15 ng
p24/ml) resulted in saturation of virus-cell binding. A
representative example is shown in Fig. 3. All nine iso-
lates bound to the target cells, using a fixed input con-
centration situated within the linear range. No differ-
ences were observed between isolates of different sub-
type, syncytium-inducing/non-syncytium-inducing (SI/
NSI) capacity, or coreceptor usage (Table 1). These input
virus concentrations were used in the binding-inhibition
studies.
Binding inhibition at different serum concentrations
In order to examine whether we can measure inhibi-
FIG. 2. Virus was incubated with PHA-stimulated PBMCs during 2 h
was measured in the supernatant (extracellular virus) and in the cells (i
results are the mean of quadruplicate experiments.tion of viral attachment to the host cells using polyclonal
sera, it was necessary to determine at what serum dilu-
r
stion the binding-inhibition experiments should be per-
formed.
A serial dilution (1:10–1:1280) of a broad cross-neutral-
izing serum (VI1456) was incubated with culture super-
natant of virus isolate VI525 (5 ng p24/ml). The percent-
age binding inhibition (% BI) was calculated for each of
the eight [serum]/[virus] combinations. The % BI at dif-
ferent serum concentrations decreased linearly (Fig. 4).
The following binding-inhibition experiments for the dif-
ferent sera were carried out using sera at the dilution of
1:20, since this is the highest dilution that gives the
highest percentage binding inhibition.
HIV-1 sera inhibit binding of HIV-1 virus isolates
(group M and group O) to PBMCs
Six broad cross-neutralizing, three limited cross-neu-
tralizing, and two nonneutralizing sera and eight HIV(2)
sera from individuals with different geographic origin
(Europe (n 5 2), Africa (n 5 2), Asia (n 5 2), South
merica (n 5 2)) at a dilution of 1:20 were examined for
heir binding-inhibition capacity of nine HIV-1 virus iso-
ates belonging to groups M (n 5 8; env clade A–H) and
(n 5 1). The results of the % BI are reported in Table
. The broad cross-neutralizing sera are able to inhibit
inding in the range from 29 to 98% BI, with an average
f 68.44%. For limited cross-neutralizing sera, an inhibi-
ion of binding ranging from 295 to 42% was observed,
. Cells were washed and treated with 0.5 mg/ml trypsin. Viral antigen
lular virus) using the Vironostika HIV-1 Antigen Microelisa system. Theat 37°Cesulting in an average of 24.48%. For nonneutralizing
era a binding inhibition was obtained in the range of
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308 BEIRNAERT ET AL.2120 to 15%, with an average of 227.72%. The percent-
age binding inhibition for the HIV(2) sera was in the
range of 2188 to 31%, with an average % BI of 22.72,
23.27, 249.35, and 29.05%, respectively, for the sera
rom European, African, Asian, and South American ori-
in, resulting in an overall average of 221.11%. The
hreshold for binding inhibition was set at 25% (average
BI HIV(2) sera 1 standard deviation).
Complying with the threshold of % BI, all six broad cross-
eutralizing sera were able to inhibit binding of all nine
FIG. 3. Virus (2.5–12.5 ng p24/ml) was incubated with PHA-stimula
described in Fig. 1. The results are the mean of duplicate experiments
T
Binding of Nine Primary Virus Isolates Belonging to Di
Genotype
(Env)
Phenoty
Coreceptor
MN B X4
VI525 GH 1 AU R5 1 X4
CA10 CRF01.AE R3 1 X4
CA13 HAU R5 1 X4
CA1 AGU R5
VI829 C R5
CA4 F2D R5
CI13 D R5
CA9 O R5Note. Viruses were incubated with PHA-stimulated PBMCs for 2 h at 37°C.
esults are the mean of duplicate experiments.rimary virus isolates, since 54 of 54 serum/virus combina-
ions scored higher than 25% BI. This results in a 100%
orrelation between broad cross-neutralization and binding
nhibition. Of the limited cross-neutralizing sera, the non-
eutralizing sera, and the HIV(2) sera only 4/27, 0/18, and
/72 serum/virus combinations, respectively, scored higher
han 25% BI. Moreover, enhancement of virus binding was
requently observed with limited cross-neutralizing (13 of 27
erum/virus combinations; 49%), nonneutralizing (14 of 18;
8%), and HIV(2) sera (49 of 72; 68%), while it was absent
MCs for 2 h at 37°C. The assay was processed in a similar way as
Genotypes and Phenotypes to the Surface of PBMCs
Input virus
concentration
(ng p24/ml)
Output virus
concentration
(pg p24/ml)I/NSI
SI 7.2 205 6 53.59
SI 8.5 139 6 46.53
SI 11.6 102 6 58.71
SI 4.0 106 6 1.22
NSI 3.3 194 6 52.70
NSI 11.25 101 6 40.70
NSI 7.4 180 6 17.22
NSI 11.3 195 6 23.13
NSI 3.7 149 6 38.96ABLE 1
fferent
pe
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dilutions examined here.
The statistical analysis showed that the difference in
the mean percentage binding inhibition between broad
cross-neutralizing and the limited cross-neutralizing, the
nonneutralizing, and the HIV(2) sera was significant
(P , 0.001) (Fig. 5).
Binding inhibition was also examined using the IgG
fraction of the six broad cross-neutralizing sera on the
VI525 virus isolate. Binding inhibition ranged from 67.5 to
95.9% BI. These results show that the binding inhibition
is mediated by antibodies and is not due to high levels of
chemokines.
DISCUSSION
In a previous study, sera from HIV-1-infected individu-
als were examined for their capacity to neutralize 17
HIV-1 primary isolates belonging to group M (env clades
A–H) and group O (Beirnaert et al., 2000). Based on their
neutralization capacity, sera could be classified into
three categories. Broad cross-neutralizing sera were
able to neutralize all genetic clades and groups, limited
cross-neutralizing sera were able to neutralize some but
not all genetic clades and groups, and nonneutralizing
sera could not cross-neutralize. The neutralizing capacity
FIG. 4. Virus was incubated with serial dilutions of heat-inactivate
processed in a similar way as described in Fig. 1. % BI 5 [1 2 (p24 con
re the mean of duplicate experiments.was IgG-related and gp120 was identified as the major
antigen against which broad cross-neutralizing antibod-
a
(ies were directed (Beirnaert et al., 2000). Since gp120 is
the viral protein required for attachment and infection of
virus in the appropriate host cell, the present study was
designed to examine whether there was a correlation
between the neutralizing capacity in these sera and the
inhibition of virus attachment to the host cell.
Several virion-binding-inhibition assays have been de-
scribed previously. In the studies described by McDou-
gal et al. (1986), Bahroui et al. (1988), and Posner et al.
1991), virus that was bound to the surface was mea-
ured through the detection of gp120. However, this can
esult in an overestimation of bound virus because shed
p120, present in the virus supernatant, also could bind
o the CD4 receptor and thus be detected. On the other
and, the preincubation of virions with anti-gp120 anti-
odies could modify the subsequent interaction of the
etection antibody through competition for the same
pitope(s), resulting in an underestimation. In the study
y Ugolini et al. (1997), these problems were solved
hrough the measurement of HLA-DR determinants ex-
ressed on the virion membrane as a virus marker.
owever, this is an indirect virus measurement. More-
ver, it is known that the incorporation of HLA is depen-
ent on the host cell in which the virus is propagated and
hus differs between T-cell line adapted (TCLA) isolates
m prior to incubation with PHA-stimulated PBMCs. The assay was
ion of test sample/p24 concentration of input virus)] 3 100. The resultsd serund primary isolates, which are cultured in PBMCs only
Bastiani et al., 1997; Saarloos et al., 1997). In the present
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310 BEIRNAERT ET AL.study’s approach, we measured virus-associated p24,
which is an internal viral protein that does not interact
with the host cell receptors and thus can not give an
overestimation of virus nor an underestimation, since
neutralizing antibodies are not directed against p24.
PBMCs were used, which are the natural target cells for
HIV infection in vivo and therefore the preferential choice
as host cell, instead of sCD4 or a continuous cell line
transfected with CD4. Virions were allowed to bind to
host cells during a 2-h period at 37°C. These conditions
resemble the incubation conditions used in the classical
neutralization assay which the authors performed and
described earlier (Beirnaert et al., 2000). The hypothesis
s that only attachment has taken place and not subse-
uent fusion, since the latter process seems to be influ-
nced by time and temperature. Based on our results
sing different incubation times (1–2 h) and tempera-
ures (4/20/37°C), no influence of either time or temper-
T
Percentage Binding Inhibition of Nine Primary Virus Isola
MN VI525 CA9 CA1
Env subtype: B GH/AU O AGU
HIV(1)
BCN
VI1291 55 56 42 55
VI1362 83 74 81 71
VI1406 66 68 83 67
VI1456 90 64 58 55
VI1785 96 70 93 66
VI1805 98 75 80 67
LCN
CA22 266 2 223 8
VI961 214 13 210 7
VI1308 210 36 21 39
NN
VI1333 261 3 213 25
VI1640 259 3 220 212
IV(2)
EU
NP867 23 12 21 213
NP868 220 16 22 216
AP
NP1067 230 21 238 217
NP1068 229 14 223 24
AS
NP1090 27 25 25 24
NP1091 282 229 2186 17
SA
NP1190 245 7 226 12
NP1191 238 16 217 15
Note. % BI 5 [1 2 (p24 concentration of test sample/p24 concentratio
f at least two independent experiments. ( ) % binding inhibition $25
ross-neutralizing sera; LCN, limited cross-neutralizing sera; NN, nonnture on the binding efficiency was observed. Moreover,
he results using trypsin treatment clearly show that
a
19.3% of the total of measured virus was located extra-
ellularly. This indicates that the attachment process
etween gp120 and the cell receptor is under investiga-
ion and that only for a minor amount of virus particles
id fusion or endocytosis occur.
Another major drawback of all previous studies de-
cribing binding inhibition is that only a few strains were
sed, which were all TCLA and which moreover exclu-
ively belonged to group M, subtype B. This study used
rimary isolates, belonging to both genotypically and
henotypically distinct groups. The nine isolates repre-
ented different clades and intersubtype recombinants
or the env gene in group M and group O. Both syncytium
nducing and non-syncytium-inducing isolates were
sed. The coreceptor use varied from exclusively R5-
ropic, to R5X4, to exclusively X4 tropic isolates.
It has been argued that inhibition of attachment of
irus to the target cell is a relatively rare mechanism of
longing to Groups M and O by HIV(1) and HIV(2) Sera
CA4 CA10 CA13 CI13 VI829
F2D CRF01.AE HAU D C
52 51 66 89 37
70 68 79 94 64
51 57 75 91 66
57 49 53 93 34
60 62 71 91 29
73 58 80 87 75
226 215 24 23 295
5 224 9 26 276
6 11 33 42 217
224 216 229 15 2120
227 233 25 8 2104
212 27 10 22 210
1 227 1 8 28
232 2116 31 24 235
222 299 24 22 236
214 222 11 24 0
254 2117 2188 298 2160
212 6 229 254 219
6 2 211 29 25
ut virus)] 3 100. The threshold of % BI is 25%. The results are the mean
% binding inhibition 1–24%; (h) % binding inhibition #0%. BCN, broad
zing sera; EU, Europe; AF, Africa; AS, Asia; SA, South America.ABLE 2
tes Be
n of inpntibody neutralization (Dimmock, 1993, 1995; McInrey,
997). However, previous studies investigated the bind-
f test sa
p
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TCLA strains to CD4. The interaction of sgp120 1 sCD4
or sgp120 1 CD41 cells is unlikely to adequately repre-
sent true virus–cell interactions, since the conformation
and quaternary structure of recombinant monomeric
sgp120 and virion-associated oligomeric gp120 are dif-
ferent and thus so is its interaction with receptor(s)
(Moore et al., 1995; Sattentau and Moore et al., 1995;
Fouts et al., 1997). The results presented here clearly
demonstrate that in neutralizing sera and their IgG-en-
riched fractions from naturally HIV-1-infected individuals,
antibodies exist that can inhibit the binding of primary
virus isolates on PBMCs. The binding inhibition ob-
served with broad cross-neutralizing sera ranged from
29 to 98%. The binding inhibition observed was both
potent, with an average of 68.44%, and broad, since the
attachment of all nine different primary viruses was in-
hibited, irrespective of the genotype or phenotype. Com-
plying with a threshold of 25%, binding inhibition was
obtained for only one limited cross-neutralizing serum on
only four isolates, with much less potency (maximal 42%
FIG. 5. BCN, broad cross-neutralizing HIV(1) sera; LCN, limited cros
serum/isolate interactions examined. % BI 5 [1 2 (p24 concentration o
erformed using the independent samples Student t test.BI). For the nonneutralizing sera, no inhibition of binding
on any of the primary virus isolates could be demon-strated. For the HIV(2) sera, only three sera were able to
inhibit binding of a different isolate. This inhibition was
also much less potent (maximal 31% BI). In conclusion, a
100% correlation between broad cross-neutralization and
the capacity to inhibit binding of primary virus strains
belonging to group M (env clades A–H) and group O was
found. The results further demonstrate that, among the
limited cross-neutralizing and the nonneutralizing sera,
enhancement of binding is a frequently occurring feature
(49–78%). However, enhancement for HIV(2) sera was
also demonstrated, suggesting that the observed en-
hancement is nonspecific.
The results presented here do not exclude the possi-
bility that some antibodies present in the polyclonal sera
neutralize by mechanisms other than inhibition of virion–
cell attachment. Infection may be neutralized in later
steps of infection. They do, however, indicate that for
broad cross-neutralizing sera a common mechanism for
neutralization exists. These antibodies share the capac-
ity to interfere in a step that is common among genotyp-
ically and phenotypically divergent strains, namely the
ralizing HIV(1) sera; NN, nonneutralizing HIV(1) sera. N 5 number of
mple/p24 concentration of input virus)] 3 100. Statistical analysis wass-neutinitial process of virus attachment to the cell. Recent
elucidation of the three-dimensional structure suggests
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312 BEIRNAERT ET AL.that the region, which is involved in this interaction with
the CD4 receptor, is conserved, but buried in a pocket
and not exposed on the protein surface. The observation
that the broad cross-neutralizing antibody response,
which is directed against conserved regions, is present
in sera from naturally infected individuals but that it takes
time to evolve can be correlated with the occluded na-
ture of a functionally important region.
MATERIALS AND METHODS
Virus isolates
Eight HIV-1 primary isolates were grown in PHA-stim-
ulated, IL-2-maintained PBMCs (Beirnaert et al., 2000).
Subtype classification of these isolates was as follows:
CA1 (env gp160, AGU; McCutchan et al., 1999); VI829
(env C2V3, C; Heyndrickx et al., 1998); CI13 (env gp160,
D); CA10 (env gp160, CRF01.AE); CA4 (env gp160, F2D);
VI525 (dual infection: env gp160, GH; Gao et al., 1998;
Janssens et al., 1994) and env gp160, AU); CA13 (env
gp160, HAU; Janssens et al., 2000); and CA9 (env gp160,
group O; Janssens et al., 1999). In addition, laboratory
isolate MN (env gp160, B), which was passaged at least
three times in PBMCs, was used. The HIV-1 gp160 en-
coding env nucleotide sequence data of CA1, CI13, CA10,
CA4, and VI525-1 were deposited in the EMBL, GenBank,
and DDBJ Nucleotide Sequence Databases under the
following accession numbers: AJ277823 (CA1), AJ277820
(CI13), AJ277818 (CA10), AJ277819 (CA4), AJ277822
(VI525-1).
Syncytium formation was determined on a MT2 cell
line, as described previously (Beirnaert et al., 2000).
Coreceptor usage was determined on GHOST cell lines,
transfected with genes coding for human CD4, one of the
eight chemokine receptors (CCR1, CCR2b, CCR3, CCR4,
CCR5, CXCR4, BOB, BONZO), which function as HIV-1
coreceptors and an indicator gene under the control of
an HIV-2 promoter, inducible by tat, which permits eval-
uation and quantitation of HIV-1 infection by flow cytom-
etry (Cecilia et al., 1998). Representative virus isolates of
the different phenotypes were used: CA1, VI829, CI13,
CA4, and CA9 are NSI and use the CCR5 coreceptor; MN
is SI and exclusively uses the CXCR4 coreceptor; CA10 is
SI and uses CCR3 and CXCR4 coreceptors; VI525 and
CA13 are SI and use CCR5 and CXCR4 coreceptors.
The p24 concentration of the virus-containing cell su-
pernatants was determined using the Vironostika HIV-1
Antigen Microelisa system (Organon Teknika, Boxtel,
The Netherlands) and an HIV-1 p24 viral lysate concen-
trate as the p24 standard (NEN, Boston, MA).
SeraIn a previous study, 66 HIV-1 sera were examined for
their neutralization capacity against 17 primary HIV-1 cisolates belonging to group M (n 5 14; env clades A–H)
and group O (n 5 3) using a PBMC-based neutralization
assay (Beirnaert et al., 2000). The sera could be grouped
into three categories based on their neutralization spec-
trum. Broad cross-neutralizing sera were able to neutral-
ize all 17 primary isolates, limited cross-neutralizing sera
were able to neutralize some but not all isolates (12–47%
of the isolates were neutralized), and nonneutralizing
sera were not able to neutralize any of the primary
isolates studied. In the present study, representative
sera of the three categories were tested: six broad cross-
neutralizing, three limited cross-neutralizing, and two
nonneutralizing. In addition, eight HIV(2) sera derived
from individuals of different origin (Europe (n 5 2), Africa
n 5 2), Asia (n 5 2), and South America (n 5 2)) were
sed as a negative control. The sera designated with
nitials VI and CA were obtained from HIV-1 patients
ttending the clinic of the Institute of Tropical Medicine,
ntwerp, Belgium, and the Center for the Study and
ontrol of Communicable Diseases, Yaounde´, Cam-
roon, respectively. The sera designated with the initials
P were obtained from HIV(2) individuals.
The IgG fraction of six sera was isolated using
abTrap G II (Pharmacia Biotech, Uppsala, Sweden)
ccording to the manufacturer’s instructions. Both the
luted IgG and the run-through fraction were desalted
nd concentrated using Centriprep 10 (Amicon, Beverly,
A) against PBS to obtain a similar IgG concentration as
he serum. The IgG fraction was examined in a similar
ay as the serum samples.
irus binding assay
A total of 100 ml of a dilution serie of virus-containing
upernatant (1–25 ng p24/ml) was mixed with 100 ml of 2-
to 3-day PHA-stimulated, IL-2-maintained PBMCs (2 3
106/ml) and incubated for 2 h at 37°C in a 5% CO2
atmosphere. After incubation, the cells were washed five
times with PBS 1 2% FCS to remove residual unbound
nput virus. Virus bound to the cell surface was lysed
sing 100 ml of detergent, provided in the antigen detec-
tion kit for 45 min at room temperature. Viral antigen was
measured using the Vironostika HIV-1 Antigen Micro-
elisa system, according to the manufacturer’s instruc-
tions. The amount of bound virus to the surface was
quantified using an HIV-1 p24 viral lysate concentrate as
standard (NEN). The samples were tested in quadrupli-
cate wells and in at least two independent experiments.
Trypsin treatment of cell-associated virus
A total of 100 ml of virus-containing supernatant (5 ng
24/ml) was mixed with 2- to 3-day PHA-stimulated,
L-2-maintained PBMCs (2 3 106/ml) and incubated for
2 h at 37°C in a 5% CO2 atmosphere. After incubation, the
ells were washed five times with PBS 1 2% FCS. Cells
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MO) for 10 min at room temperature (Valenzuela et al.,
1997). The effect of trypsin was neutralized by the addi-
tion of 1/6 vol of 100% FCS. The cell supernatant was
harvested and cells were washed two times before lysis.
Both the lysed cells and the cell supernatant were ex-
amined for the presence of viral antigen as described
above. The experiments were performed in quadrupli-
cate.
Binding-inhibition assay
A total of 100 ml of supernatant of virus-infected
BMCs (3–12 ng p24/ml) was preincubated with 100 ml of
a 1:20 dilution of heat-inactivated sera (30 min at 56°C)
for 1 h at 37°C in a 5% CO2 atmosphere. Subsequently,
100 ml of PHA-stimulated, IL-2-maintained PBMCs (2 3
106/ml) was added. After 2 h of incubation, the cells were
ashed and virus was lysed and measured as described
bove.
For every binding-inhibition experiment, a dilution se-
ies of input virus (1–25 ng p24/ml) was included in
uadruplicate wells to determine the binding efficiency
or each stock of donor PBMCs used. A standard curve
as calculated correlating the amount of input virus and
he observed OD450nm value. This curve was used to
etermine with what input concentration a certain
D450nm value in the test samples correlated. Using this
method of calculation, the variation in binding efficiency
observed between different donor PBMCs could be
countered. The percentage binding inhibition was calcu-
lated as % BI 5 [1 2 (p24 concentration of test sample/
p24 concentration of input virus)] 3 100. The different
serum/virus combinations were assayed in duplicate
wells and in at least two independent experiments.
Statistical analysis
The statistical analysis on the difference between the
means of binding inhibition was performed using the
independent samples Student t test. The level of signif-
icance was set at P , 0.05. The statistical analysis was
performed using the SPSS program (SPSS Inc., Chicago,
IL).
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